Literature DB >> 28104077

Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.

Mary S Vaughan Sarrazin, Michael Jones, Alexander Mazur, Peter Cram, Padmaja Ayyagari, Elizabeth Chrischilles.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28104077      PMCID: PMC8330835          DOI: 10.1016/j.jacc.2016.11.023

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  4 in total

1.  Comparisons of two-part models with competitors.

Authors:  P A Lachenbruch
Journal:  Stat Med       Date:  2001-04-30       Impact factor: 2.373

2.  Matching by propensity score in cohort studies with three treatment groups.

Authors:  Jeremy A Rassen; Abhi A Shelat; Jessica M Franklin; Robert J Glynn; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

3.  Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.

Authors:  Inmaculada Hernandez; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-07       Impact factor: 21.873

4.  Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry.

Authors:  Matthew R Reynolds; Vidal Essebag; Peter Zimetbaum; David J Cohen
Journal:  J Cardiovasc Electrophysiol       Date:  2007-04-19
  4 in total
  2 in total

Review 1.  The role of personalized atrial modeling in understanding atrial fibrillation mechanisms and improving treatment.

Authors:  Konstantinos N Aronis; Rheeda Ali; Natalia A Trayanova
Journal:  Int J Cardiol       Date:  2019-01-31       Impact factor: 4.164

2.  Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.

Authors:  Akiomi Yoshihisa; Yu Sato; Takamasa Sato; Satoshi Suzuki; Masayoshi Oikawa; Yasuchika Takeishi
Journal:  BMC Cardiovasc Disord       Date:  2018-01-25       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.